Global WholeHealth Partners Corp. (OTC: GWHP), a multinational supplier of over 70+ FDA Approved Diagnostic Tests, attains breakthrough on rising neurological disease.
"This could simply be described as nothing short of a Medical Breakthrough in Alzheimer's Disease Diagnostic Testing for us," said Charles Strongo, CEO of Global WholeHealth Partners Corp. (OTC:GWHP).
Global WholeHealth Partners now has the means to identify and test for Alzheimer's disease using a Micro-Well Reader or Lateral Flow Test to measure the certain brain enzymes during the data collection process used in a positive diagnosis. This was disclosed in an 8K filed March 21, 2021 which can be found by clicking here.
“We believe this announcement couldn’t come at a better time for us as we are partnering with Nunzia Pharmaceutical and their products for Neurological disorders,” said Mr. Strongo
The number of Americans living with Alzheimer's is growing — and growing fast. More than 6 million Americans of all ages have Alzheimer's. An estimated 6.2 million Americans age 65 and older are living with Alzheimer's dementia in 2021. Seventy-two percent are age 75 or older.
https://www.alz.org/alzheimers-dementia/facts-figures
Alzheimer’s disease is currently ranked as the sixth leading cause of death in the United States, but recent estimates indicate that the disorder may rank third, just behind heart disease and cancer, as a cause of death for older people… Common behavioral symptoms of Alzheimer’s include sleeplessness, wandering, agitation, anxiety, and aggression . . . The damage initially appears to take place in the hippocampus and the entorhinal cortex, parts of the brain essential in forming memories.
https://www.nia.nih.gov/health/alzheimers-disease-fact-sheet
Alzheimer’s Disease
There are many causes of dementia, and Alzheimer’s disease is the most common by far in the United States and many other countries. Alzheimer’s disease can be suspected clinically, and certain brain scans can almost make the diagnosis a certainty.
https://www.brightfocus.org/alzheimers/article/what-dementia
“Early detection for Alzheimer's disease is not only crucial for patients and their quality of life, but this data is also used by researchers to seek out commonalities, causes and hopefully cures,” commented Strongo.
Mr. Charles Strongo, the Chairman and CEO of Global WholeHealth Partners Corp., said, "The Company's goal is to offer the fastest and most reliable in-vitro diagnostic tests on the market, while keeping ahead in R&D, by offering FDA Approved Troponin I Whole Blood, Influenza A & B, and Strep A. The Company also has international testing, which is not sold in the USA, with an FDA Certificate of Exportability (2260-11-2019) for tests like ZIKA, Rapid Ebola, Rapid Dengue Fever Antibody, and Antigen, Rapid Tuberculosis (TB), Rapid Malaria, and many other rapid tests."
GWHP develops, manufactures, and markets in vitro diagnostic (IVD) tests for OTC, or consumer-use as well as professional rapid diagnostic point-of-care (POC) test kits for hospitals, physicians’ offices, and medical clinics in the US and abroad. The Company has the capacity to deliver hundreds of thousands of tests, and can ramp up to 1 million tests per day. Currently, the Company has 56 products FDA approved and many are Approved for OTC use, and 9 POC products approved by the FDA.
Media Contact:
Name: Charles Strongo,
CEO, Global WholeHealth Partners Corp.
Email: Sales@gwhpcorp.com
Phone for Sales: 949-324-6691
www.gwhpcorp.com
This press release contains "forward-looking statements.” Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Global WholeHealth Partners Corp. (OTC: GWHP) Signs a Binding MOU With Pan Probe Biotech and AvantGen to Develop the Newest COVID-19 Antigen Test on the Market: 8K Filed on 09/21/2021
Released On: 10/25/2021
Views: 2590
Global WholeHealth Partners Provides Competitive Pricing on Bulk COVID-19 Testing Kits and PPE Supplies
Released On: 10/24/2021
Views: 2556
Global WholeHealth Partners Is The Trusted Provider of Wholesale PPE Supplies and COVID-19 Diagnostic Testing Kits
Released On: 10/22/2021
Views: 2619
Order Medical Grade COVID-19 Diagnostic Testing Kits and PPE Supplies Wholesale Online from Global WholeHealth Partners
Released On: 10/20/2021
Views: 2546
Global WholeHealth Partners Corp (OTC: GWHP) Proudly Announces Its New Manufacturing Facility Which is Able to Triple the Production Volume for the Potential Sales from Walmart, Amazon, eBay and Shopify as Stated in the 8K Filing 08/03/2021
Released On: 10/19/2021
Views: 2564
With COVID-19 Vaccination Rates Increasing Global WholeHealth Partners Continues To Source Premium PPE Supplies and Testing Kits
Released On: 10/18/2021
Views: 2535
Global WholeHealth Partners Sources Superior PPE Supplies and COVID-19 Diagnostic Testing Kits Available for Wholesale Purchase
Released On: 10/16/2021
Views: 2510
Global WholeHealth Partners Corp. (OTC: GWHP), is Approved to Sell Through Walmart, Amazon, eBay and Shopify as Stated in the 8K Filing 08/03/2021; Global's Newly Designed Tests Are Now Ready for the Launch into the Retail Marketplace
Released On: 10/14/2021
Views: 2465
Purchase Superior COVID-19 Diagnostic Testing Kits And Personal Protective Equipment Online from Global WholeHealth Partners
Released On: 10/14/2021
Views: 3119
Global WholeHealth Partners Corp. (OTC: GWHP) Has Been Approved to Sell Its Products Through Walmart and Amazon as Stated in the 8K Filing 08/03/2021; Global's Newly Designed Tests Are Now Ready for the Launch Into the Retail Marketplace
Released On: 10/12/2021
Views: 2486
GWHP Corp Sources Wholesale PPE Supplies and COVID 19 Testing Kits In The Age of Coronavirus and Rising COVID-19 Cases
Released On: 10/10/2021
Views: 2935
Order Bulk PPE Supplies and COVID 19 Diagnostic Testing Kits from Global WholeHealth Partners
Released On: 10/4/2021
Views: 2815
Shop Wholesale PPE Supplies and COVID-19 Tests Available from GWHP Corp Online Today
Released On: 9/30/2021
Views: 2526
Global WholeHealth Partners Corp (OTC: GWHP) Partners With Pan Probe Biotech and AvantGen to Develop the Newest COVID19 Antigen Test on the Market; 8k Filed on 09/21/2021
Released On: 9/29/2021
Views: 2287
GWHP Continues to Source COVID-19 Tests and PPE Supplies As The Delta Variant Continues to Spread
Released On: 9/27/2021
Views: 2781
Partnerships with Key Players Enables GWHP Corp To Source PPE Supplies and COVID-19 Diagnostic Testing Kits
Released On: 9/14/2021
Views: 2818
Global WholeHealth Partners Corp (OTC:GWHP) Now Able to Sell Through Shopify’s Multibillion Dollar Online Platform as Stated in 8k Filing 08/05/21
Released On: 9/14/2021
Views: 2178
Global WholeHealth Partners Provides Wholesale PPE Supplies and COVID-19 Diagnostic Testing Kits
Released On: 9/12/2021
Views: 2829